Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in PsA therapeutics.
There will be more than 6 million prevalent cases of PsA in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast.
There are 14 leading marketed drugs for the treatment of PsA, Janssen is the key player in the PsA landscape with five marketed products.
R&D activity in PsA is robust globally, with three products in the pre-registration phase in the US, Japan, and EU, and 14 products in Phase III development across the global markets.
Commercial sponsors dominate clinical trial development in PsA, with the US emerging as the key country for conducting Phase III trials in PsA.
During the past 12 months, three mergers and acquisitions, and five strategic alliances deal involving companies developing PsA assets have been completed.
Scope
GlobalData’s PsA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the PsA market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Findings
Disease Overview
Disease Etiology
Epidemiology Overview
Epidemiology Overview - Total Prevalent Cases of PsA in 2023
Treatment Overview
Treatment Guidelines
Treatment Algorithm
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in PsA
Marketed Drugs - Overview by Mechanism of Action
Marketed Drugs - Overview by Route of Administration
Marketed Drugs - Overview by Molecule Type
Marketed Drug Profile: AbbVie’s Humira
Marketed Drug Profile: Janssen’s Stelara
Marketed Drug Profile: Amgen’s Enbrel
Marketed Drug Profile: Novartis’s Cosentyx
Marketed Drug Profile: Janssen’s Remicade
Marketed Drug Profile: Janssen’s Simponi
Marketed Drug Profile: AbbVie’s Skyrizi
Marketed Drug Profile: Pfizer’s Xeljanz
Marketed Drug Profile: UCB’s Cimzia
Marketed Drug Profile: Eli Lilly’s Taltz
Marketed Drug Profile: Janssen’s Tremfya
Marketed Drug Profile: AbbVie’s Rinvoq
Pricing and Reimbursement Assessment
Marketed Drugs - Annual Cost of Therapy for Intravenous Formulations in PsA
Marketed Drugs - Annual Cost of Therapy for Oral Formulations in PsA
Marketed Drugs - Annual Cost of Therapy
Marketed Drugs - Time to Pricing and Reimbursement for Adalimumab
Marketed Drugs - Time to Pricing and Reimbursement for Abatacept
Marketed Drugs - Time to Pricing and Reimbursement for Certolizumab
Marketed Drugs - Time to Pricing and Reimbursement for Etanercept
Marketed Drugs - Time to Pricing and Reimbursement for Golimumab
Marketed Drugs - Time to Pricing and Reimbursement for Guselkumab
Marketed Drugs - Time to Pricing and Reimbursement for Infliximab
Marketed Drugs - Time to Pricing and Reimbursement for Ixekizumab
Marketed Drugs - Time to Pricing and Reimbursement for Risankizumab
Marketed Drugs - Time to Pricing and Reimbursement for Secukinumab
Marketed Drugs - Time to Pricing and Reimbursement for Ustekinumab
Marketed Drugs - Time to Pricing and Reimbursement for Apremilast
Marketed Drugs - Time to Pricing and Reimbursement for Tofacitinib
Marketed Drugs - Time to Pricing and Reimbursement for Upadacitinib
Pipeline Drugs Assessment
Pipeline Drugs Overview - Pre-registration and Phase III Pipeline Drugs in PsA
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Route of Administration
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in PsA
Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Musculoskeletal Disorders and in PsA
Clinical Trials Assessment
Clinical Trials in PsA - Historical Overview
Clinical Trials in PsA - Overview by Phase
Clinical Trials in PsA - Overview by Status
Clinical Trials in PsA - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in PsA - Trials with a Virtual Component
Clinical Trials in PsA - Geographic Overview
Clinical Trials in PsA - Single-Country and Multinational Trials by Region
Clinical Trials in PsA - Top Sponsors with Breakdown by Phase
Clinical Trials in PsA - Top Sponsors with Breakdown by Status
Clinical Trials in PsA - Overview by Endpoint Status
Clinical Trials in PsA - Overview by Race and Ethnicity
Clinical Trials in PsA - Enrollment Data
Clinical Trials in PsA - Overview of Sites by Geography
Clinical Trials in PsA - Top 20 Countries for Trial Sites